Advertisement

Pharmacy World and Science

, Volume 24, Issue 5, pp 169–171 | Cite as

Impact of drug policy on the use of parenteral cephalosporins in Italy

  • Gianfranco DamianiEmail author
  • Bruno Federico
  • Marco Oradei
  • Gian Carlo Vanini
  • Rino Bellocco
Article

Abstract

Objective: To evaluate the effects of the 1998 revision of CUF Note 55 on doctors" prescribing behaviour and drug costs with regard to intramuscularly administered cephalosporins.Method: National data on drug use between January 1998 and June 2000 were provided by the Drug Utilisation Monitoring Centre of the Ministry of Health. The Anatomic Therapeutic Chemical classification and the Defined Daily Dose methodology, as well as population estimates obtained from the Italian National Statistics Institute were used to define consumption as the number of defined daily doses per 1000 inhabitants per day. The cost of these antibiotic medications was determined using the wholesale price reported in Informatore Farmaceutico. Italian inflation rates were used to annuitize the expenditure. “STATA 6.0” software was used for all statistical analyses.Results: The use of cefonicid rose dramatically after the revision (+ 136.3%), whereas the utilisation of the other active ingredients decreased. A decrease of 5.6% in the expenditure for all parenteral cephalosporins was observed in this period while the same figure increased by 2.3% after one year.Conclusion: The exclusion of cefonicid from a restricted list appears to have significantly affected doctors' prescribing practices, while the effect on drug expenditure was contradictory.

Defined daily dose Drug policy Drug use Intramuscularly administered cephalosporins Italy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cars O, Molstad S, Melander A. Variation in antibiotic use in the European Union. Lancet 2001;357:1851–3.PubMedGoogle Scholar
  2. 2.
    Osservatorio nazionale sull'impiego dei medicinali. L'uso dei farmaci in Italia-1°Rapporto nazionale-I semestre 2000. Rome: Ministero della Sanità, Dipartimento per la Valutazione dei Medicinali e la Farmacovigilanza, 2001Google Scholar
  3. 3.
    Dipartimento per la Valutazione dei Medicinali e la Farmacovigilanza. Elenco delle ”Note” aggiornate e revisionate dalla Commissione Unica del Farmaco. Bollettino d'Informazione sui Farmaci 1998;2:20–1.Google Scholar
  4. 4.
    WHO Collaborating Centre for Drug Statistics Methodology. ATC Index with DDDs. Oslo: WHO; 2000.Google Scholar
  5. 5.
    http://www.istat.it (8 August 2001).Google Scholar
  6. 6.
    L'Informatore Farmaceutico. Milano: OEMF, 2000.Google Scholar
  7. 7.
    Gill PS, Freemantle N, Bero L, Haaijer-Ruskamp F, Markela M, Barjesteh KP. GP's prescribing behaviour may be affected by drug promotion. BMJ 1996; 313: 367.Google Scholar
  8. 8.
    World Health Organization. World Health Organization Report on Infectious Diseases 2000. Overcoming antimicrobial resistance http://www.who.int/infectious-disease-report/ 2000/ index.html. (6 August 2001)Google Scholar
  9. 9.
    Seppala H, Klaukka T, Vuopio-Varkil J, Muotiala A, Helenius H, Lager K et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med 1997;337(7): 441–6.PubMedGoogle Scholar
  10. 10.
    Dipartimento per la Valutazione dei Medicinali e la Farmacovigilanza. Le nuove note CUF. Bollettino D'informazione sui Farmaci 2000;5–6 (Sept-Dec):20–1.Google Scholar

Copyright information

© Kluwer Academic Publishers 2002

Authors and Affiliations

  • Gianfranco Damiani
    • 1
    Email author
  • Bruno Federico
    • 1
  • Marco Oradei
    • 1
  • Gian Carlo Vanini
    • 1
  • Rino Bellocco
    • 2
  1. 1.Institute of HygieneCatholic UniversityRomeItaly
  2. 2.Karolinska InstitutetStockholmSweden

Personalised recommendations